AbbVie sharpens immunology focus with $10.9 billion Apoge…

AbbVie announced its acquisition of Apogee Therapeutics for $10.9 billion, marking its largest buyout in over five years. This move aims to enhance AbbVie's treatment pipeline for inflammatory diseases like atopic dermatitis and asthma, amid increasing biotech deal-making due to upcoming patent expirations of key drugs. The acquisition provides AbbVie access to zumilokibart, a promising drug that could significantly boost its immunology revenue, which surpassed $30 billion in 2025. The deal, which offers a 49.49% premium on Apogee shares, is expected to close in Q3 2026 and is seen favorably by analysts for its potential in the market.

Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv

Test tubes are seen in front of a displayed Abbvie logo in this illustration

Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Purchase Licensing Rights, opens new tab

Companies
Abbvie Inc

Apogee Therapeutics Inc

GSK plc

Show more companies

June 22 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday it would buy Apogee Therapeutics (APGE.O), opens new tab for $10.9 billion, the company's largest buyout in more than five years, as it seeks to bolster its treatment pipeline for inflammatory ‌diseases like atopic dermatitis and asthma.

The acquisition, one of the largest biotech deals of the year, underscores the surge in pharmaceutical dealmaking, as companies race to build their portfolios ahead of looming patent expirations on blockbuster treatments.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

AbbVie has bet on acquisitions to counter declining demand for former top-selling drug Humira following biosimilar competition while bracing for patent expirations of immunology blockbusters Skyrizi and Rinvoq.

Recent deals include the $10.1 billion ⁠ImmunoGen deal for ovarian cancer drug Elahere and Cerevel Therapeutics for a clutch of experimental treatments for neurological and psychiatric diseases.

The Apogee acquisition grants AbbVie access to its lead drug candidate, zumilokibart, an experimental treatment targeting a range of inflammatory diseases. If approved, the therapy could expand AbbVie's position in immunology, its largest business and a key driver of future growth.

AbbVie's immunology franchise generated more than $30 billion in revenue in 2025, up 14% from the previous year, as strong growth in Skyrizi and Rinvoq made up for a 49% drop in sales of Humira.

AbbVie CEO Robert Michael called the acquisition an "excellent fit" with the company's strategy and ‌said ⁠Apogee's pipeline had the potential to achieve "mega-blockbuster" peak sales, which the company defines as more than $10 billion in annual sales.

AbbVie has offered $135.11 per Apogee share held, which implies a 49.49% premium to the stock's Thursday close. AbbVie said it will fund the deal through debt.

Shares of Waltham, Massachusetts-headquartered Apogee were up 50% in early trading, while AbbVie was up ⁠4.6%.

J.P. Morgan analyst Chris Schott said the deal is likely to be well-received by investors, who have been looking for more late-stage growth assets.

Analysts said zumilokibart could offer a potentially more convenient option to Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster Dupixent.

Unlike Dupixent, ⁠which is typically administered every two weeks in atopic dermatitis, zumilokibart is being studied as a subcutaneous injection given once every three or six months, likely offering a substantial reduction in dosing frequency.

"We believe the ⁠deal makes sense and that AbbVie is an ideal acquirer to maximize zumilokibart's potential," RBC Capital Markets analyst Brian Abrahams said.

The transaction is expected to close in the third quarter and add to adjusted earnings per share in 2032, AbbVie said.

Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sriraj Kalluvila

Our Standards: The Thomson Reuters Trust Principles., opens new tab

X
Facebook
Linkedin
Email
Link

Purchase Licensing Rights

AbbVie sharpens immunology focus with $10.9 billion Apogee deal

Read Next / Editor's Picks